作者: Marta Moreira , Olga Castro , Melissa Palmieri , Sofia Efklidou , Stefano Castagna
DOI: 10.1080/21645515.2016.1263409
关键词: Pneumococcal disease 、 Pediatrics 、 Incidence (epidemiology) 、 Vaccination coverage 、 Pneumococcal conjugate vaccine 、 Medicine 、 Private market 、 Vaccination 、 Pneumococcal conjugate vaccination 、 Clinical effectiveness
摘要: ABSTRACTHigher-valent pneumococcal conjugate vaccines (PCVs) were licensed from 2009 in Europe; similar worldwide clinical effectiveness was observed for PCVs routine use. Despite a proven medical need, PCV vaccination Southern Europe remained suboptimal until 2015/16.We searched PubMed manuscripts published between and mid-2016. Included had to contain data about invasive disease (IPD) incidence, or coverage with higher-valent PCVs. This review represents the first analysis of impact on overall IPD European countries (Portugal, Spain, Italy, Greece, Cyprus).Vaccination Portuguese private market peaked around 2008 at 75% (children ≤ 2 years) but declined 63% 2012. In Madrid, 95% (2007–2012) dropped 67% (2013/14; children after funding termination May recently introduced national immunisation program (NIP) Portugal (...